Interesting Stock Signals: Altera (ALTR)
Post# of 81
Posted On: 05/31/2015 9:45:02 PM
Shares of Altera Corp. (ALTR) touched a new 52-week high in after-hours trading Friday, continuing the positive momentum generated by media reports indicating that tech giant Intel Corp. (INTC) is near a deal to acquire the company for as much as $54.00 per share.
ALTR posted sales of $435.5 million and net income of $94.9 million, or $0.31 per diluted share for the first quarter 2015
ALTR, a semiconductor company, designs and sells programmable logic devices (PLDs), HardCopy application-specific integrated circuit (ASIC) devices, power system-on-chip devices (PowerSoCs), pre-defined design building blocks, and associated development tools.
More about Altera Corp. (ALTR) at www.altera.com
**
Pharmacyclics a wholly-owned subsidiary of AbbVie Inc. (ABBV), said that the results of the Phase III HELIOS trial found that when added, ibrutinib (IMBRUVICA) enhanced the treatment effect of standard bendamustine and rituximab treatment, resulting in a significant improvement in the outcomes for chronic lymphocytic leukemia and small lymphocytic lymphoma patients and reducing the risk of progression or death by 80% compared to placebo in combination with bendamustine and rituximab.
According to ABBV's Pharmacyclics, patients also experienced a higher overall response rate, including achieving a higher rate of complete responses, after a median follow-up of 17 months
Separately, ABBV's Pharmacyclics also announced that interim results from the ongoing Phase Ib/II PCYC-1129 study suggest that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. cGVHD is a life-threatening condition in which newly transplanted cells attack the patient's body
IMBRUVICA, jointly developed and commercialized by ABBV's Pharmacyclics and Janssen Biotech, Inc., is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase.
ABBV is a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.
More about AbbVie Inc. (ABBV) at www.abbvie.com
**
Integrated Silicon Solution Inc. (ISSI) ISSI received a previously announced non-binding offer by Cypress Semiconductor Corp. (CY) to acquire all of its common stock for a cash purchase price of $19.75 per share, ISSI said on Friday that it has entered into an amendment to its merger agreement with Uphill Investment Co., increasing the merger consideration to $20.00 per share in cash.
Cypress Semiconductor announced after the closing bell that it sent a letter to ISSI's Board of Directors with a new offer of $20.25 per share in cash for the company.
Cypress is asking that ISSI's board of directors immediately determine that the terms of the attached Merger Agreement (in the letter) constitute a "Superior Proposal" under the terms of the Agreement and Plan of Merger, dated March 12, 2015, by and between ISSI and Uphill Investment Co.
ISSI designs, develops, and markets high performance specialty integrated circuits for the automotive, communications, industrial/medical and digital consumer industries.
More about Integrated Silicon Solution Inc. (ISSI) at www.issi.com
**
Crown Equity Holdings Inc. (CRWE) has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )
The company is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company’s services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms.
CRWE‘s growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.
The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
ALTR posted sales of $435.5 million and net income of $94.9 million, or $0.31 per diluted share for the first quarter 2015
ALTR, a semiconductor company, designs and sells programmable logic devices (PLDs), HardCopy application-specific integrated circuit (ASIC) devices, power system-on-chip devices (PowerSoCs), pre-defined design building blocks, and associated development tools.
More about Altera Corp. (ALTR) at www.altera.com
**
Pharmacyclics a wholly-owned subsidiary of AbbVie Inc. (ABBV), said that the results of the Phase III HELIOS trial found that when added, ibrutinib (IMBRUVICA) enhanced the treatment effect of standard bendamustine and rituximab treatment, resulting in a significant improvement in the outcomes for chronic lymphocytic leukemia and small lymphocytic lymphoma patients and reducing the risk of progression or death by 80% compared to placebo in combination with bendamustine and rituximab.
According to ABBV's Pharmacyclics, patients also experienced a higher overall response rate, including achieving a higher rate of complete responses, after a median follow-up of 17 months
Separately, ABBV's Pharmacyclics also announced that interim results from the ongoing Phase Ib/II PCYC-1129 study suggest that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. cGVHD is a life-threatening condition in which newly transplanted cells attack the patient's body
IMBRUVICA, jointly developed and commercialized by ABBV's Pharmacyclics and Janssen Biotech, Inc., is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase.
ABBV is a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.
More about AbbVie Inc. (ABBV) at www.abbvie.com
**
Integrated Silicon Solution Inc. (ISSI) ISSI received a previously announced non-binding offer by Cypress Semiconductor Corp. (CY) to acquire all of its common stock for a cash purchase price of $19.75 per share, ISSI said on Friday that it has entered into an amendment to its merger agreement with Uphill Investment Co., increasing the merger consideration to $20.00 per share in cash.
Cypress Semiconductor announced after the closing bell that it sent a letter to ISSI's Board of Directors with a new offer of $20.25 per share in cash for the company.
Cypress is asking that ISSI's board of directors immediately determine that the terms of the attached Merger Agreement (in the letter) constitute a "Superior Proposal" under the terms of the Agreement and Plan of Merger, dated March 12, 2015, by and between ISSI and Uphill Investment Co.
ISSI designs, develops, and markets high performance specialty integrated circuits for the automotive, communications, industrial/medical and digital consumer industries.
More about Integrated Silicon Solution Inc. (ISSI) at www.issi.com
**
Crown Equity Holdings Inc. (CRWE) has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )
The company is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company’s services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms.
CRWE‘s growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.
The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)Altera Corp. (ALTR) Stock Research Links
Scroll down for more posts ▼